Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper

Multiple Sclerosis

Volumn 22, Issue 11, 2016, Pages 1386-1396

  Otero Romero, Susana ^a   Sastre Garriga, Jaume ^a   Comi, Giancarlo ^b   Hartung, Hans Peter ^c   Soelberg Sørensen, Per ^d   Thompson, Alan J ^e   Vermersch, Patrick ^f   Gold, Ralf ^g   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c Department of Orthopedic Surgery   (Germany)

^d University of Copenhagen   (Denmark)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIV LILLE   (France)

^g ST JOSEF HOSPITAL   (Germany)

Author keywords

Multiple sclerosis; pharmacological treatment; review; spasticity

Indexed keywords

BACLOFEN; DANTROLENE; DIAZEPAM; GABAPENTIN; NABIXIMOLS; PHENOL; TIZANIDINE; 4 AMINOBUTYRIC ACID; AMINE; AMINO ACID RECEPTOR BLOCKING AGENT; ANALGESIC AGENT; CANNABIDIOL; CENTRAL MUSCLE RELAXANT; CLONIDINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; DRONABINOL; BENZODIAZEPINE; BOTULINUM TOXIN A; PLACEBO;

ADD ON THERAPY; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERANCE; HUMAN; LOCAL THERAPY; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPASTICITY; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; COMPLICATION; CONSENSUS DEVELOPMENT; DRUG COMBINATION; INTRASPINAL DRUG ADMINISTRATION; CHEMICAL STRUCTURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; LIVER FUNCTION; MUSCLE CONTRACTION; MUSCLE CRAMP; MUSCLE SPASM; MUSCLE TONE; MUSCLE WEAKNESS; PARESTHESIA; PHARMACOLOGICAL SCIENCE; PRACTICE GUIDELINE; REIMBURSEMENT; RETICULAR FORMATION; SAMPLE SIZE; SINGLE DRUG DOSE; TREMOR; WEAKNESS; XEROSTOMIA;

AMINES; ANALGESICS; BACLOFEN; CANNABIDIOL; CLONIDINE; CYCLOHEXANECARBOXYLIC ACIDS; DANTROLENE; DIAZEPAM; DRONABINOL; DRUG COMBINATIONS; EXCITATORY AMINO ACID ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; INJECTIONS, SPINAL; MULTIPLE SCLEROSIS; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; PHENOL;

EID: 84989898286     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458516643600     Document Type: Review

References (99)

1. Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004; 10: 589-595.
2. Biering-Sorensen F, Nielsen JB, Klinge K,. Spasticity-assessment: A review. Spinal Cord 2006; 44: 708-722.
3. Haselkorn JK, Balsdon RC, Fry WD, et al. Overview of spasticity management in multiple sclerosis: Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med 2005; 28: 167-199.
4. Platz T, Eickhof C, Nuyens G, et al. Clinical scales for the assessment of spasticity, associated phenomena, and function: A systematic review of the literature. Disabil Rehabil 2005; 27: 7-18.
5. Haugh AB, Pandyan AD, Johnson GR,. A systematic review of the Tardieu Scale for the measurement of spasticity. Disabil Rehabil 2006; 28: 899-907.
6. Priebe MM, Sherwood AM, Thornby JI, et al. Clinical assessment of spasticity in spinal cord injury: A multidimensional problem. Arch Phys Med Rehabil 1996; 77: 713-716.
7. Hobart JC, Riazi A, Thompson AJ, et al. Getting the measure of spasticity in multiple sclerosis: The Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 2006; 129: 224-234.
8. Syczewska M, Lebiedowska MK, Pandyan AD,. Quantifying repeatability of the Wartenberg pendulum test parameters in children with spasticity. J Neurosci Methods 2009; 178: 340-344.
9. Thompson AJ, Jarrett L, Lockley L, et al. Clinical management of spasticity. J Neurol Neurosurg Psychiatry 2005; 76: 459-463.
10. Lapeyre E, Kuks JB, Meijler WJ,. Spasticity: Revisiting the role and the individual value of several pharmacological treatments. NeuroRehabilitation 2010; 27: 193-200.
11. Amatya B, Khan F, La Mantia L, et al. Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database Syst Rev 2013; 2: CD009974.
12. Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces-Revised recommendations 2004. Eur J Neurol 2004; 11: 577-581.
13. Summary of product characteristics: Oral baclofen, http://www.medicines.org.uk/emc/medicine/23850 (. accessed December 2015).
14. Basmajian JV,. Lioresal (baclofen) treatment of spasticity in multiple sclerosis. Am J Phys Med 1975; 54: 175-177.
15. Jerusalem F,. Double-blind study on the antispastic effect of beta-94-chlorphenyl)-gamma aminobutyric acid (CIBA) in multiple sclerosis. Nervenarzt 1968; 39: 515-517 (in German).
16. Brar SP, Smith MB, Nelson LM, et al. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehabil 1991; 72: 186-189.
17. Cartlidge NE, Hudgson P, Weightman D,. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci 1974; 23: 17-24.
18. Feldman RG, Kelly-Hayes M, Conomy JP, et al. Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. Neurology 1978; 28: 1094-1098.
19. From A, Heltberg A,. A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975; 51: 158-166.
20. Hudgson P, Weightman D,. Baclofen in the treatment of spasticity. Br Med J 1971; 4: 15-17.
21. Orsnes GB, Sorensen PS, Larsen TK, et al. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand 2000; 101: 244-248.
22. Roussan M, Terrence C, Fromm G,. Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy. Pharmatherapeutica 1985; 4: 278-284.
23. Sachais BA, Logue JN, Carey MS,. Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol 1977; 34: 422-428.
24. Sawa GM, Paty DW,. The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci 1979; 6: 351-354.
25. Levine IM, Jossmann PB, DeAngelis V,. Liorseal, a new muscle relaxant in the treatment of spasticity-A double-blind quantitative evaluation. Dis Nerv Syst 1977; 38: 1011-1015.
26. Dario A, Tomei G,. A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf 2004; 27: 799-818.
27. Summary of product characteristics: Tizanidine, https://www.medicines.org.uk/emc/medicine/22602 (. accessed December 2015).
28. Emre M, Leslie GC, Muir C, et al. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol Neurosurg Psychiatry 1994; 57: 1355-1359.
29. Nance PW, Sheremata WA, Lynch SG, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997; 54: 731-736.
30. Vakhapova V, Auriel E, Karni A,. Nightly sublingual tizanidine HCl in multiple sclerosis: Clinical efficacy and safety. Clin Neuropharmacol 2010; 33: 151-154.
31. Smith C, Birnbaum G, Carter JL, et al. Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994; 44: S34-S42.
32. Lapierre Y, Bouchard S, Tansey C, et al. Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci 1987; 14: 513-517.
33. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology 1994; 44: S70-S78.
34. Rinne U,. Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy. Curr Ther Res Clin Exp 1980; 28: 827-836.
35. Eyssette M, Rohmer F, Serratrice G, et al. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 1988; 10: 699-708.
36. Hoogstraten MC, van der Ploeg RJ, vd BW, et al. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurol Scand 1988; 77: 224-230.
37. Newman PM, Nogues M, Newman PK, et al. Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol 1982; 23: 31-35.
38. Rice GP., Tizanidine vs,. baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1989; 16: 451.
39. Smolenski C, Muff S, Smolenski-Kautz S,. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 1981; 7: 374-383.
40. Stien R, Nordal HJ, Oftedal SI, et al. The treatment of spasticity in multiple sclerosis: A double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol Scand 1987; 75: 190-194.
41. Wagstaff AJ, Bryson HM,. Tizanidine: A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997; 53: 435-452.
42. Neill RW,. Diazepam in the relief of muscle spasm resulting from spinal-cord lesions. Ann Phys Med 1964; (Suppl 1): 33-38.
43. Schmidt RT, Lee RH, Spehlmann R,. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1976; 39: 350-356.
44. Basmajian JV, Shankardass K, Russell D, et al. Ketazolam treatment for spasticity: Double-blind study of a new drug. Arch Phys Med Rehabil 1984; 65: 698-701.
45. Basmajian JV, Shankardass K, Russell D,. Ketazolam once daily for spasticity: Double-blind cross-over study. Arch Phys Med Rehabil 1986; 67: 556-557.
46. Kita M, Goodkin DE,. Drugs used to treat spasticity. Drugs 2000; 59: 487-495.
47. Solaro C, Lunardi GL, Capello E, et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 1998; 51: 609-611.
48. Solaro C, Uccelli MM, Guglieri P, et al. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler 2000; 6: 192-193.
49. Dunevsky A, Perel AB,. Gabapentin for relief of spasticity associated with multiple sclerosis. Am J Phys Med Rehabil 1998; 77: 451-454.
50. Cutter NC, Scott DD, Johnson JC, et al. Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000; 81: 164-169.
51. Mueller ME, Gruenthal M, Olson WL, et al. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 1997; 78: 521-524.
52. Kamen L, Henney HR III, Runyan JD,. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin 2008; 24: 425-439.
53. Clinical practice guideline on the management of people with multiple sclerosis. Barcelona: Catalan Health Agency for Quality and Assessment (AQuAS); Multiple Sclerosis Center of Catalonia (Cemcat); Departament de Salut, Generalitat de Catalunya, 2012.
54. Summary of product characteristics: Dantrolene, https://www.medicines.org.uk/emc/medicine/24339 (. accessed December 2015).
55. Ladd H, Oist C, Jonsson B,. The effect of Dantrium on spasticity in multiple sclerosis. Acta Neurol Scand 1974; 50: 397-408.
56. Gambi D, Rossini P, Calenda G, et al. Dantrolene sodium in the treatment of spasticity caused by multiple sclerosis or degenerative myelopathies: A double-blind, crossover study in comparison with placebo. Curr TherRes Clin Exp 1983; 33: 835-840.
57. Sheplan L, Ishmael C,. Spasmolytic properties of dantrolene sodium: Clinical evaluation. Mil Med 1975; 140: 26-29.
58. Gelenberg AJ, Poskanzer DC,. The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology 1973; 23: 1313-1315.
59. Tolosa ES, Soll RW, Loewenson RB,. Letter: Treatment of spasticity in multiple sclerosis with dantrolene. JAMA 1975; 233: 1046.
60. Pinder RM, Brogden RN, Speight TM, et al. Dantrolene sodium: A review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977; 13: 3-23.
61. Russo E, Guy GW,. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66: 234-246.
62. Meinck HM, Schonle PW, Conrad B,. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989; 236: 120-122.
63. Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12: 639-645.
64. Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-29.
65. Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial. J Neurol 2006; 253: 1337-1341.
66. Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14: 290-296.
67. Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-1407.
68. ®) (nabiximols). Mult Scler 2012; 18: 219-228.
69. ®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122-1131.
70. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10: 417-424.
71. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434-441.
72. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-1526.
73. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1664-1669.
74. Wade DT, Collin C, Stott C, et al. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010; 16: 707-714.
75. Karst M, Wippermann S, Ahrens J,. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 2010; 70: 2409-2438.
76. Farrar JT, Troxel AB, Stott C, et al. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: A post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008; 30: 974-985.
77. Fleuren JF, Voerman GE, Erren-Wolters CV, et al. Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 2010; 81: 46-52.
78. Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: A systematic review. CMAJ 2008; 178: 1669-1678.
79. National Clinical Guideline Centre. Multiple sclerosis: Management of multiple sclerosis in primary and secondary care. London: National Institute for Health and Care Excellence, 2014.
80. Pathak MS, Nguyen HT, Graham HK, et al. Management of spasticity in adults: Practical application of botulinum toxin. Eur J Neurol 2006; 13 (Suppl. 1): 42-50.
81. Borg-Stein J, Pine ZM, Miller JR, et al. Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations. Am J Phys Med Rehabil 1993; 72: 364-368.
82. Grazko MA, Polo KB, Jabbari B,. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995; 45: 712-717.
83. Finsterer J, Fuchs I, Mamoli B,. Automatic EMG-guided botulinum toxin treatment of spasticity. Clin Neuropharmacol 1997; 20: 195-203.
84. Snow BJ, Tsui JK, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: A double-blind study. Ann Neurol 1990; 28: 512-515.
85. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: A prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 68: 707-712.
86. Wood KM,. The use of phenol as a neurolytic agent: A review. Pain 1978; 5: 205-229.
87. Copp EP, Harris R, Keenan J,. Peripheral nerve block and motor point block with phenol in the management of spasticity. Proc R Soc Med 1970; 63: 937-938.
88. Wassef MR,. Interadductor approach to obturator nerve blockade for spastic conditions of adductor thigh muscles. Reg Anesth 1993; 18: 13-17.
89. Awad EA,. Phenol block for control of hip flexor and adductor spasticity. Arch Phys Med Rehabil 1972; 53: 554-557.
90. Akkaya T, Unlu E, Alptekin A, et al. Neurolytic phenol blockade of the obturator nerve for severe adductor spasticity. Acta Anaesthesiol Scand 2010; 54: 79-85.
91. Coffey JR, Cahill D, Steers W, et al. Intrathecal baclofen for intractable spasticity of spinal origin: Results of a long-term multicenter study. J Neurosurg 1993; 78: 226-232.
92. Middel B, Kuipers-Upmeijer H, Bouma J, et al. Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997; 63: 204-209.
93. Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517-1521.
94. Penn RD,. Intrathecal baclofen for spasticity of spinal origin: Seven years of experience. J Neurosurg 1992; 77: 236-240.
95. Intrathecal baclofen pump for spasticity: An evidence-based analysis. Ont Health Technol Assess Ser 2005; 5: 1-93.
96. Browne RA, Catton DV,. The use of intrathecal phenol for muscle spasms in multiple sclerosis. A description of two cases. Can Anaesth Soc J 1975; 22: 208-218.
97. Cain HD,. Subarachnoid phenol block in the treatment of pain and spasticity. Paraplegia 1965; 3: 152-160.
98. Jarrett L, Nandi P, Thompson AJ,. Managing severe lower limb spasticity in multiple sclerosis: Does intrathecal phenol have a role? J Neurol Neurosurg Psychiatry 2002; 73: 705-709.
99. Pinder C, Bhakta B, Kodavali K,. Intrathecal phenol: An old treatment revisited. Disabil Rehabil 2008; 30: 381-386.